No profile data available.
Bioxytran, Inc. (BIXT) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Needham, United States, with about 2 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$2.12 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $2.70 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans.
Bioxytran reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$2.70 million as of October 8, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Gossamer Bio, Inc. (GOSS), Grace Therapeutics, Inc. (GRCE), Cadrenal Therapeutics, Inc. (CVKD).